Pyxis Oncology Inc. (PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, has a couple of catalysts to watch in the coming months.
The company's lead drug candidate is PYX-201, an investigational antibody-drug conjugate (ADC), which is under a phase I trial in multiple types of solid tumors. So far, 72 subjects have been dosed in the trial. Preliminary data, including efficacy, safety, and pharmacokinetics (PK) of PYX-201 is expected to be shared in the fall of 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com